Literature DB >> 31352982

Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma.

Alex Chan1, Ahmet Dogan2.   

Abstract

Entities:  

Keywords:  DLBCL prognosis; Immunophenotype; Mutational profile

Mesh：

Substances：

Year:  2019        PMID： 31352982      PMCID： PMC6668922          DOI： 10.1016/j.path.2019.03.012

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN： 1875-9157


× No keyword cloud information.
  78 in total

1.  BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Authors:  Javeed Iqbal; Paul N Meyer; Lynette M Smith; Nathalie A Johnson; Julie M Vose; Timothy C Greiner; Joseph M Connors; Louis M Staudt; Lisa Rimsza; Elaine Jaffe; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Wing C Chan
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

2.  Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.

Authors:  Nalan Akyurek; Aysegul Uner; Mustafa Benekli; Ibrahim Barista
Journal:  Cancer       Date:  2011-12-27       Impact factor: 6.860

3.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

4.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

Review 5.  The emerging role of immune checkpoint inhibition in malignant lymphoma.

Authors:  Ida Hude; Stephanie Sasse; Andreas Engert; Paul J Bröckelmann
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

6.  Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.

Authors:  Beenu Thakral; L Jeffrey Medeiros; Parth Desai; Pei Lin; C Cameron Yin; Guilin Tang; Joseph D Khoury; Shimin Hu; Jie Xu; Sanam Loghavi; Bei Hu; Yasuhiro Oki; Shaoying Li
Journal:  Eur J Haematol       Date:  2017-01-30       Impact factor: 2.997

7.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Authors:  Eric D Jacobsen; Jeff P Sharman; Yasuhiro Oki; Ranjana H Advani; Jane N Winter; Celeste M Bello; Gary Spitzer; Maria Corinna Palanca-Wessels; Dana A Kennedy; Pamela Levine; Jing Yang; Nancy L Bartlett
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

8.  Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.

Authors:  Anita Kumar; Matthew A Lunning; Zhigang Zhang; Jocelyn C Migliacci; Craig H Moskowitz; Andrew D Zelenetz
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998

9.  Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.

Authors:  John Rossi; Patrick Paczkowski; Yueh-Wei Shen; Kevin Morse; Brianna Flynn; Alaina Kaiser; Colin Ng; Kyle Gallatin; Tom Cain; Rong Fan; Sean Mackay; James R Heath; Steven A Rosenberg; James N Kochenderfer; Jing Zhou; Adrian Bot
Journal:  Blood       Date:  2018-06-12       Impact factor: 22.113

10.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440
View more
  3 in total

1.  Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients.

Authors:  Anna Nydegger; Urban Novak; Marie-Noëlle Kronig; Myriam Legros; Sacha Zeerleder; Yara Banz; Ulrike Bacher; Thomas Pabst
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

2.  HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression

Authors:  YuYing Cui; Chao Lv; Yu Wen; Dongmei Zhao; Yu Yang; Hongbin Qiu; Chennan Wang
Journal:  Balkan Med J       Date:  2021-12-20       Impact factor: 2.021

3.  Case Report: Identification of Potential Prognosis-Related TP53 Mutation and BCL6-LPP Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases.

Authors:  Yi Zhang; Liyuan Ma; Jie Liu; Huijuan Zhu; Lin Lu; Kan Deng; Wenbin Ma; Hui Pan; Renzhi Wang; Yong Yao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-26       Impact factor: 5.555
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.